Your browser doesn't support javascript.
loading
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu, Hiroaki; Murakami, Eriko; Oyanagi, Jun; Shibaki, Ryota; Kaki, Takahiro; Takase, Eri; Tanaka, Masanori; Harutani, Yuhei; Yamagata, Nao; Okuda, Yuka; Furuta, Katsuyuki; Sugimoto, Takeya; Teraoka, Shunsuke; Hayata, Atsushi; Tokudome, Nahomi; Ozawa, Yuichi; Mori, Keita; Koh, Yasuhiro; Yamamoto, Nobuyuki.
Afiliación
  • Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Murakami E; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Oyanagi J; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Shibaki R; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Kaki T; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Takase E; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Tanaka M; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Harutani Y; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Yamagata N; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Okuda Y; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Furuta K; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Sugimoto T; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Teraoka S; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Hayata A; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Tokudome N; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Ozawa Y; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Mori K; Clinical Trial Management Department, Shizuoka Cancer Center, Shizuoka, Japan.
  • Koh Y; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
  • Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Oncologist ; 25(4): e679-e683, 2020 04.
Article en En | MEDLINE | ID: mdl-32297443
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Pulmonares / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Pulmonares / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido